Hepatitis C is diagnosed through a simple two-step blood testing process: first a screening test checks for antibodies, then a follow-up test confirms whether the virus is actively present. Most people can get a definitive answer from a single blood draw, and the CDC recommends that every adult 18 and older get screened at least once in their lifetime.
The Two-Step Testing Process
The first test is an antibody test. Your immune system produces antibodies when it encounters the hepatitis C virus, and these antibodies remain in your blood for life, even if the infection clears on its own. The screening test checks for these antibodies and is about 99% sensitive, meaning it catches nearly every case. A negative result generally means you’ve never been infected, and no further testing is needed.
If the antibody test comes back positive, it doesn’t necessarily mean you have an active infection right now. It means you were exposed to the virus at some point. The next step is an HCV RNA test, which looks for the virus’s genetic material in your blood. This test tells you whether the virus is still present and actively replicating. A positive RNA result confirms a current infection. A negative RNA result means the virus is no longer detectable, either because your body cleared it naturally or because of prior treatment.
What “Antibody Positive, RNA Negative” Means
Getting a positive antibody result followed by a negative RNA result can feel confusing, but it’s actually good news. It means there’s no laboratory evidence of active infection. This result points to one of two explanations: your body successfully fought off the virus on its own (which happens in roughly 20% to 37% of acute infections), or the initial antibody test was a false positive.
False positives are more common when the overall infection rate in a tested population is low. If you and your doctor want to know which explanation applies, a second antibody test using a different testing method can help. If that second test also comes back positive, it suggests you genuinely had hepatitis C in the past and cleared it. If it’s negative, the original result was likely a false positive.
Rapid and Reflex Testing Options
Not every diagnosis requires two separate appointments. Many labs now use reflex testing, where a single blood draw serves both steps. The lab runs the antibody test first, and if it’s positive, the same blood sample is automatically forwarded for RNA testing. You and your doctor receive both results without a second visit or second needle stick.
For settings like community health clinics or outreach programs, a rapid fingerstick test called OraQuick can deliver antibody results in 20 to 40 minutes. In studies of high-risk patients, this test showed sensitivity as high as 100% and specificity above 99%. During a large-scale outbreak investigation in New Hampshire, it correctly matched standard lab results in over 99% of cases. A positive rapid test still requires a follow-up RNA test to confirm active infection, but it removes the barrier of needing a lab visit for the initial screen.
The Window Period After Exposure
Timing matters when testing for hepatitis C. The virus’s genetic material (RNA) becomes detectable in blood within days to two weeks after exposure. Antibodies, however, take much longer to appear, typically two to six months. This gap is called the window period, and it’s the reason an antibody test taken too soon after a possible exposure might come back falsely negative. If you’ve had a recent high-risk exposure, your doctor may order an RNA test directly rather than waiting for antibodies to develop.
Who Should Get Tested
The CDC recommends universal screening for all adults 18 and older at least once, and for all pregnant people during each pregnancy. Beyond that one-time screen, certain groups should be tested more often or whenever a specific risk applies:
- Current or former injection drug users who shared needles, syringes, or other equipment. Those who currently inject drugs should get tested routinely, not just once.
- People living with HIV.
- People on long-term hemodialysis.
- Recipients of blood transfusions, organ transplants, or clotting factor products before 1992 (before widespread screening of the blood supply).
- Healthcare workers after needle sticks or other exposures to blood that may contain the virus.
- Infants born to a parent with hepatitis C.
Liver Enzyme Clues
Hepatitis C is sometimes suspected based on routine blood work before a specific test is ever ordered. Liver enzymes called ALT and AST, which are part of standard metabolic panels, can be elevated in people with chronic hepatitis C. A pattern of elevated ALT and AST (called a hepatocellular pattern) is strongly associated with a positive hepatitis C antibody result. In one primary care study, this pattern of liver enzyme elevation was linked to more than seven times higher odds of testing positive for hepatitis C antibodies. Elevated liver enzymes alone don’t diagnose hepatitis C, but they’re often the red flag that prompts a doctor to order the antibody test in the first place.
Assessing Liver Damage After Diagnosis
Once active hepatitis C is confirmed, the next question is how much the virus has affected your liver. Liver damage from hepatitis C develops as fibrosis, the buildup of scar tissue that gradually replaces healthy liver cells. Doctors stage this damage on a scale from F0 (no scarring) to F4 (cirrhosis, or extensive scarring).
The gold standard for measuring fibrosis has traditionally been a liver biopsy, where a small needle removes a tiny piece of liver tissue for examination. But most people today are assessed with noninvasive methods instead. The most common is a FibroScan, an ultrasound-based device that measures liver stiffness in kilopascals (kPa). Normal liver stiffness starts around 2.5 kPa. Values in the range of 5.2 to 8.9 kPa suggest significant fibrosis, while values between 10.1 and 17.6 kPa point toward cirrhosis. The test takes only a few minutes, feels like an ultrasound, and requires no needles or recovery time.
Doctors can also estimate fibrosis using simple blood-based scoring systems. The FIB-4 score uses your age, platelet count, and liver enzymes (AST and ALT) to generate a number that correlates with fibrosis severity. The APRI score works similarly, using the ratio of AST to platelet count. These scores won’t replace imaging or biopsy in every situation, but research shows they can identify advanced fibrosis and cirrhosis with enough accuracy to spare many patients from more invasive testing. A biopsy is typically reserved for cases where clinical symptoms and noninvasive results don’t line up.
Genotype Testing Is Often Optional Now
Hepatitis C has several genotypes (genetic strains), and until recently, identifying which one you carried was essential for choosing the right treatment. That’s changed. Modern antiviral treatments are pangenotypic, meaning they work across all major strains of the virus. As a result, genotype testing is no longer required before starting first-line treatment in many cases. Your doctor may still order it in specific clinical situations, but for most people, the path from diagnosis to treatment no longer depends on it.
How Long the Process Takes
With reflex testing, the turnaround from blood draw to a confirmed diagnosis can be as short as two days, though some labs take up to three weeks depending on testing volume. Labs that batch-process RNA tests (waiting until they have enough samples to run the assay) tend to be on the slower end. Once you have a confirmed positive RNA result and fibrosis assessment, the time from diagnosis to starting treatment has ranged from about 52 to 83 days in published studies, though this varies widely depending on healthcare access and how quickly you’re connected with a specialist.